Dopamine receptors in Parkinson's disease: imaging studies
Stoessl, A.J.; de la Fuente-Fernández, R.úl.
Advances in Neurology 91: 65-71
2003
ISSN/ISBN: 0091-3952 PMID: 12442664 Document Number: 564695
Document emailed within 1 workday
Related Documents
Albin, R.L.; Nichols, T.E.; Frey, K.A. 2002: Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease JAMA 288(3): 311Ahlskog, J.Eric.; Maraganore, D.M.; Uitti, R.J.; Uhl, G.R. 2002: Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease JAMA 288(3): 311; Author Reply 312-3
Krivonos, O.V.; Fedorova, N.V.; Chigir', I.P. 2004: A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 104(1): 24-30
Shinotoh, H.; Aotsuka, A.; Inoue, O.; Suzuki, K.; Fukuda, H.; Iyo, M.; Yamazaki, T.; Tateno, Y.; Hirayama, K.; Nohara, N. 1991: Imaging of dopamine D1 and D2 receptors by a high resolution positron emission tomography Advances in Experimental Medicine and Biology 287: 249-253
Gekht, A.B. 2002: Use of dopamine agonists in the treatment of Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 102(9): 54-58
Jenner, P. 2005: A novel dopamine agonist for the transdermal treatment of Parkinson's disease Neurology 65(2 Suppl 1): S3-S5
Molho, E.S.; Factor, S.A.; Weiner, W.J.; Sanchez-Ramos, J.R.; Singer, C.; Shulman, L.; Brown, D.; Sheldon, C. 1995: The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease Journal of Neural Transmission. Supplementum 45: 225-230
Kish, S.; Rajput, A.; Gilbert, J.; Rozdilsky, B.; Chang, L.J.; Shannak, K.; Hornykiewicz, O. 1987: GABA-dopamine relationship in Parkinson's disease striatum Advances in Neurology 45: 75-77
Gerfen, C.R. 2000: Dopamine-mediated gene regulation in models of Parkinson's disease Annals of Neurology 47(4 Suppl 1): S42
Sweet, R.D.; Wasterlain, C.; McDowell, F.H. 1974: Piribedil--an oral dopamine agonist for treatment of Parkinson's disease Transactions of the American Neurological Association 99: 258-260
Olanow, C.Warren. 2002: The role of dopamine agonists in the treatment of early Parkinson's disease Neurology 58(4 Suppl 1): S33-S41
Hornykiewicz, O. 2001: Dopamine and Parkinson's disease. a personal view of the past, the present, and the future Advances in Neurology 86: 1-11
Löschmann, P.A.; Kunow, M.; Wachtel, H. 1992: Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease Journal of Neural Transmission. Supplementum 38: 55-64
2002: Dopamine agonist is effective in Parkinson disease not only against tremor. Depression is also improved MMW Fortschritte der Medizin Suppl. 2: 88
Streifler, M.; Vardi, Y.; Kesten, M.; Oberman, Z.; Herzberg, M. 1972: Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease Israel Journal of Medical Sciences 81(5): 597-601
Szczudlik, A.; Rudzińska, M. 2007: Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? Yes Neurologia i Neurochirurgia Polska 41(2 Suppl 1: S6-S9
Bode, M. 2009: Dopamine agonist therapy in early Parkinson's disease. a survey of a Cochrane review Ugeskrift for Laeger 171(41): 2996-2999
Creese, I.; Sibley, D.R.; Leff, S.E. 1984: Agonist interactions with dopamine receptors: focus on radioligand-binding studies Federation Proceedings 43(13): 2779-2784
Buscaino, G.A.; Sori, A.; Campanella, G. 1972: Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa Revue Neurologique (Paris) 127(2): 301-302
Li, Y.; Zhang, X.; Han, X.; Guo, M.; Zou, M.; Wang, L.; Li, Y.; Xiao, Y.; Zeng, W.; Song, Q. 2014: Association between polymorphism of dopamine β-hydroxylase gene and Parkinson's disease in Uygurs and Hans of Xinjiang Zhonghua Yi Xue Za Zhi 94(11): 808-812